Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides to be used in the treatment of cutaneous leishmaniasis infections.
September 29, 2020
By: Contract Pharma
Contract Pharma Staff
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a provider of biopharmaceutical contract development and manufacturing services, has entered into a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections. This project is supported by the Global Health Innovative Technology (GHIT) Fund.
Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides, which provides a strong immunostimulatory effects. CpG-D35 will be used to stimulate innate immune response in patients as an adjunct to chemotherapies in treating complicated cutaneous leishmaniasis (CL) and post-kala-azar dermal leishmaniasis (PKDL), persisting parasitic infections causing severely disfiguring and stigmatizing skin lesions.
“We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis,” said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka. “We are pleased to be a trusted and innovative partner to our client, while reinforcing our dedication in improving the health of humankind.”
Over one billion people are at risk of leishmaniasis worldwide, which is transmitted by sandfly bites. Cutaneous leishmaniasis is the most common presentation, with about one million new cases annually. Post-kala-azar dermal leishmaniasis is a complication of visceral leishmaniasis, which can appear months or years after completing treatment.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !